Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like I was right. Day traders prepped for the uplisting. Short opening spike and a huge sell off back below opening SP.
Typical, but I'm confident InMed has some awesome news coming, possibly tomorrow--at least in the next few weeks.
$5 MAYBE by the end of the year if we see a spike like we did in Dec 2017. The current trend puts InMed at around $2 in Oct 2018.
I've seen uplisting to TSX actually drop SP for some companies after a short rise. We'll see $2.20 if InMed keeps up the good work and posts some meaningful updates on their pipline / biosynthesis.
Bill C45 Passes in the Canadian Senate's 2nd reading.
Vote result on second reading of Bill #C45. Yeas: 44 Nays: 29 #SenCA #cdnpoli pic.twitter.com/rT0LKSJs4Q
— Senate of Canada (@SenateCA) March 22, 2018
Good read, Coors / Beer companies aren't the only ones that will be climbing aboard. We'll start to see Big Pharma companies taking stakes in the cannabis sector soon too.
I'll take All-In's overly enthusiastic posts over your constant complaining any day LOL.
A little info about ROTH...
Since 1992:
Raised over $45 billion for small-cap public and private companies
Completed approximately 300 merger, acquisition and advisory assignments
My prediction for Monday. We see a drop to the 1.10's with accumulation into the 1.20's again ending around $1.25. People will be getting ready for Tuesday news.
If news breaks tomorrow, we see a run up to the $1.40's again. I don't think insider's will be selling again until later this year, but you never know--depends on the importance of the news coming--if it's irrefutably bad ass news such as upscaling biosynthesis news, then we could see a run into the $1.80's or higher with some insider selling that won't even matter.
As always, I could be wrong, but with the current situation, chances are high for regular news here on out.
If news doesn't break this week, chances are we see +/- $0.10 around the current SP of $1.25 until next week.
Not with InMed pushing to better themselves for the uplisting.
Eric Adams Bionsynthesis Interview
Merry Jane Interview
I don't think this was posted on the hub yet, just thought I'd share this with you guys.
Sent in a suggestion to Inmed to do a Reddit AMA on the r/weedstocks subreddit. I think it's an excellent way to get some free exposure to a large group of investors (42,559 subreddit subscribers). If you'd like to see this happen to, send Inmed a comment as well.
Back sooner than I expected too. I'm glad to see people have the same faith in this company as I do.
Hell yeah, I missed the 60's, but I picked some up at 0.75
Looks like I was pretty damn close to calling that bottom.
Yep, I'm out for several weeks. So many longs trying to pump this up out of fear. The entire stock market is scared right now and alot of dumping is ahead.
yep looks like it. ask is chancing the bid hard
Yeah I've been in/out a dozen times on IMLFF. Looking for the bottom of this pit before I jump back in.
If you decided to eat this drop and not sell during the 1st or 2nd drop, I suggest you hold on tight. You sell, you lose, it's that simple. You hold and average down when the price drops even further, you'll be ok. Don't expect this to take off anytime soon. I called 0.70's awhile back and it looks like I'm probably gonna be pretty damn close. News will break soon in a week or so, price will jump 0.10 to around 0.95, there will be a quick sell and a drop to 0.75 +/- 0.05, and it'll even out around 0.85 - 0.95, unless it breaks $1 again, but I doubt it'll have the spunk like the new year spike.
SP is still healthy and inline with the previous several months minus the new year anomaly.
Aw shit, didn't know it was CA law to be non-profit to grow cannabis for medicinal use. I get that right? Probably why there isn't shit out there on Cultivar Inc.
Meh, that chart is bogus. Canopy Growth, Sunniva, Aphria, and Aurora are going to buy damn near everyone out and in the end Inmed will rule with cannabinoid biosynthesis. They'll probably be bought out before that happens though.
Games. It'll drop on the open.
Typically news breaks in the morning and if it's big enough they'll halt trading.
I've sold IMLFF roughly 20 times in a year or so and re-bought everytime.
Here is my call from earlier, we'll get some decent news in a couple weeks--right when PPS hits the 70's. I'm guessing it'll be an update on biosynthesis and/or announcement of ph1. We might see some intermediate news about a partnership. I've been watching weed stocks with a hawk eye and big boys are starting to merge, buy, and invest in the smaller growers/distributors and now biopharma. Emerald just dumped $400,000 into Nemus, Aurora / Cannimed / Newstrike takeover, Hiku (DOJA / TS Brandco), Aphria-led private placement with DOJA, Aphria’s acquisition of Broken Coast and so forth.
IMO, it's only a matter of time before expansion hungry companies come after Inmed. I know I would if I was in Aphria / Aurora / Canopy / Sunniva's position. Rec will probably rely heavily on dry flowers and extracts but the trend is toward extracts. Extracts will only get cheaper at production facilities increase capacity. Eventually we'll see a minimum where extractors will be turning to biosynthesis.
O it'll probably go a lot lower. No news, low volume, members cashing in and scaring off potential investors.
I think IMLFF is going to be quietly/steadily dropping down into the $0.70 range the next several weeks.
Fine with me, I called $0.70's before we see some hardcore consolidation and tick up.
Massive bids at 1.10
If they did this I'd doubt their biosynthesis patent less.
It's all good even though InMed currently has nothing to do with recreational (although they could make biosynthesis available for creating THC extracts if they wanted to). I first stumbled on InMed when I became interested in Colorado going recreational back in 2014. My interest in recreational didn't stop me from buying InMed but I probably wouldn't have read about it if it hadn't been for my recreational interest. The same phenomena will happen with many investors who are first attracted to recreational MJ in Canada.
Anyone care to reflect on what happened in Decemeber? I'm sure there were plenty of people here who saw the openings in Decemeber where we saw $0.30 increases at times. Wealthy day trader games?
CHART
The focus is most likely going to shift toward recreational the closer we get to legalization in Canada. If investors tie up their money in other, more appealing stocks, you won't be seeing a maxed out PPS anytime soon. I might be wrong about the drop below $1 BTW--I don't feel to confident in that prediction. It'll definitely drop if there is another insider cashing in next week though LOL.
IMO it is highly doubtful we'll see $1.30 anytime soon. Now I'm not saying sell by any means. It'll definitely go above $1.30 again and if you are a long investor I wouldn't worry about the ups and downs right now.
O it'll probably go a lot lower. No news, low volume, members cashing in and scaring off potential investors.
I think IMLFF is going to be quietly/steadily dropping down into the $0.70 range the next several weeks.
Good luck to you all today. May the force be with you.
Inmed Pharmaceuticals $4.55 million Financing. Jeff Charpentier Submitted Jan 17 Form D
January 17, 2018 - By reb123z
Inmed Pharmaceuticals Financing
Inmed Pharmaceuticals Inc., Corporation just filed form D announcing $4.55 million equity financing. This is a new filing. Inmed Pharmaceuticals was able to fundraise $1.63 million so far. That is 35.90 % of the round of financing. The total offering amount was $4.55 million. The financing form was filed on 2018-01-17. The reason for the financing was: US dollar amounts herein have been converted from Canadian dollars based on the 0.7979 Bank of Canada daily exchange rate in effect on 1-3-18. Total Remaining to be Sold represents the aggregate exercise price of all warrants sold in the offering.. The fundraising still has about $2.92 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Inmed Pharmaceuticals is based in British Columbia – Canada. The company’s business is Pharmaceuticals. The form was signed by Jeff Charpentier Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: Suite 340 – 200 Granville Street, Vancouver, A1, British Columbia, Canada, V6c 1S4. Eric A. Adams is the related person in the form and it has address: Suite 340 – 200 Granville Street, Vancouver, A1, British Columbia, Canada, V6c 1S4. Link to Inmed Pharmaceuticals Filing: 000172832818000001.
Analysis of Inmed Pharmaceuticals Offering
On average, firms in the Pharmaceuticals sector, sell 60.90 % of the total offering amount. Inmed Pharmaceuticals sold 35.90 % of the offering. The fundraising is still open. The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 193.83 % bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this offering is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Inmed Pharmaceuticals Also
The Form D signed by Jeff Charpentier might help Inmed Pharmaceuticals Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Article
No explanation?
Yep, holding long for now. I imagine we'll probably see volume like this until we get some news flowing. I imagine Inmed will time it with tax returns lol.
US was closed today. I'm surprise IMLFF got that much action today.
Looks like some company insider's sold some options. Happens with huge spikes in PPS and new companies. Same just happened to IMLFF (InMed Pharmaceuticals).
Browsing through Supreme's SEDAR documents you'll find this...
Grant of Stock Options
In addition to the aforementioned leadership changes, the Company granted 3,005,000 stock options
(each an “Option”) to various employees, directors and consultants pursuant to the Company’s
Employee Stock Option Plan (the “Plan”). Each Option has an exercise price of $1.45 and is exercisable
at any time prior to September 25, 2022, subject to the terms and conditions of the Plan.
Did he provide any insight into J.P. conference.